Search results
Results from the WOW.Com Content Network
Pfizer's stock was down 2% in early trading Thursday. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs ...
Pfizer posted strong earnings in the third quarter as investors worry about the stock's value. Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure [Video] Skip to main ...
Here is whether Pfizer stock might be a buy today -- and why. Pfizer's pandemic boom (and bust) shouldn't haunt the stock much longer. Dividend investors will focus on Pfizer's current dividend ...
The good news is that declining sales should soon end, and Pfizer can start replenishing its top line with growth from non-pandemic-related products. ... Before you buy stock in Pfizer, consider ...
Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55. Pfizer Just Reassured Investors, but Is the Stock a Buy? Skip to ...
Pfizer’s stock hit an all-time high of $61.25 in December 2021 as its COVID shot, as well as its antiviral treatment Paxlovid, helped billions return to work, school, and public life.
Pfizer beat on earnings in the first quarter of 2024, giving its stock a much-needed 7% boost Wednesday.The company reported $14.9 billion in revenue, down 19% compared to last year. That beat ...
On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board of Directors. Starboard Value said they had scheduled a meeting with ...